Funakoshi Yohei

Funakoshi Yohei | Funakoshi Yohei

Affiliation and department：
Job title： Assistant Professor

Research field (4)： Immunology , Hematology and oncology , Tumor diagnostics and therapeutics , Tumor biology

Research theme for competitive and other funds (7)：

2024 - 2027 BCRレパトア解析を用いた造血幹移植後免疫再構築の解明
2023 - 2027 B細胞を軸とした免疫チェックポイント阻害の有害事象の包括的機序解明と効果の推定
2023 - 2025 Establishment of a platform for high-throughput CAR-T cell generation for gastric cancer
2022 - 2025 Development of novel cancer immunotherapies targeting functional MDSCs
2020 - 2023 Investigating whether antibody production contributes to immune-related adverse events using an acellular protein synthesis system

Show all

Papers (81)：

Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Tomoo Itoh, Masanori Teshima, Ken-Ichi Nibu, Kazuko Sakai, et al. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer. Asia-Pacific journal of clinical oncology. 2024
Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, et al. Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines. EJHaem. 2024. 5. 4. 661-668
Hironobu Goto, Taro Oshikiri, Takashi Kato, Yoshiaki Nagatani, Yohei Funakoshi, Yasufumi Koterazawa, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, et al. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial). PLOS ONE. 2024. 19. 4. e0299742-e0299742
Goh Ohji, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, et al. Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d). Frontiers in immunology. 2024. 15. 1468760-1468760
船越洋平, 藥師神公和, 大路剛, 松谷隆治, 北條渉, 酒井博則, 松本咲耶, 渡部まりか, 北尾章人, 齊藤泰之, et al. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab. 日本臨床腫瘍学会学術集会(CD-ROM). 2024. 21st. 3. 504-516

ｍore...

MISC (62)：

今村善宣, 能勢拓, 大幡真也, 乙井一典, 森健太, 辻高寛, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, et al. 進行・再発・転移の固形腫瘍における血栓塞栓症と出血リスク PROVE-emboli試験post-hoc解析. 日本血栓止血学会誌. 2024. 35. 2. 336-336
長谷善明, 船越洋平, 南博信. 進行胃癌に対する免疫療法と分子標的治療の新展開びまん性胃癌における遺伝子変異と腫瘍免疫微小環境から考える複合免疫療法. 日本消化器病学会雑誌. 2024. 121. 臨増総会. A51-A51
長谷善明, 船越洋平, 南博信. びまん性胃癌における遺伝子変異と腫瘍免疫微小環境から考える複合免疫療法. 日本消化器病学会雑誌(Web). 2024. 121
船越佑大, 神田壮平, 秋濱晋, 堀川洋平, 東海林琢男, 下田直威. A CASE OF INFLAMMATORY MYOFIBROBLASTIC TUMOR OF THE BLADDER TREATED WITH PARTIAL CYSTECTOMY. 泌尿器科紀要. 2023. 69. 7. 179-182
今村善宣, 能勢拓, 大幡真也, 森健太, 乙井一典, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, 船越洋平, et al. 進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析. 日本血栓止血学会誌. 2023. 34. 2. 195-195

ｍore...

Lectures and oral presentations (21)：

Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
(63rd ASH Annual Meeting 2021)
Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
(ASCO-SITC 2019)
TP-0903, a multikinase inhibitor of AXL/JAK2/Aurora B, reduces inflammatory breast
(2018San Antonio Breast Cancer Symposium 2018)
肺動脈原発内膜肉腫の3例
(第1回日本腫瘍循環器学会学術集会 2018)
本邦での大腸癌患者におけるマイクロサテライト不安定性検査の有用性についての検討
(第77回日本癌学会学術集会 2018)

ｍore...

Education (2)：

- 2013 Kobe University Graduate School of Medicine
1998 - 2004 Nihon University School of Medicine

Professional career (1)：

博士(医学) (神戸大学)

Work history (2)：

2017/04 - 現在神戸大学医学部附属病院
2015/04 - 2017/03 MD Anderson Cancer Center Breast Medical Oncology

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page